• EORTC Quality of Life Group celebrating 40 years

  • EORTC Item Library provides considerable coverage of CTCAE side effects

    EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds

  • PRESS RELEASE: Better treatment for better heath: lifting the veil on treatment optimisation
    Categories: ,

    PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation

  • Lung

    MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

  • Melanoma

    PRESS RELEASE: European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients

  • Breast cancer study - Ameera-study_EORTC-Sanofi-BIG-AFT

    PRESS RELEASE: Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

  • HRH Princess Dina Mired - ECRF & EORTC Honorary President
    Categories: ,

    PRESS RELEASE: HSH Prince Albert II cedes Honorary Presidency of the EORTC Research Fund to HRH Princess Dina Mired

  • SISAQOL press release - illustration

    PRESS RELEASE: Generating recommendations for the design, analysis and interpretation of patient- reported outcome (PRO) data for cancer clinical trials: the launch of SISAQOL-IMI